Bottom line: A strong patent infringement case is not always a profitable business case. Legal analysis can show whether a product infringes, but licensing value depends on the accused infringer’s revenue, the economic importance of the patented feature, and whether the cost of enforcement is justified.

‍

A Strong Patent Is Not a Profitable One: Legal vs Business Cases of Patent Infringement

Why the business value of patent enforcement is determined by who you are suing, not by whether you can win.

Patent law and patent strategy are not the same discipline. They share vocabulary and they share a court system. But they operate according to entirely different logics — and confusing them is one of the more expensive mistakes a company can make.

The legal question in patent infringement is binary: does the accused product fall within the scope of the claims? Courts answer it with claim charts, expert testimony, prosecution history, and the constructions of claim terms. The answer is either yes or no.

The business question is different. It is not whether you can win. It is whether winning is worth doing.

That distinction sounds obvious. In practice, it gets missed with remarkable consistency — particularly in licensing-out strategy, where a patent owner evaluates whether to pursue an accused infringer. The instinct is to anchor on the strength of the infringement case. A well-constructed claim chart showing clear element-by-element mapping across the accused product reads as a commercial asset. The stronger the claim chart, the stronger the opportunity.

The claim chart is necessary. It is not sufficient. The variable that determines the commercial outcome of a licensing-out strategy is not claim strength. It is the revenue the accused infringer is actually generating from the accused product — and the size of the company behind it.

The claim chart tells you whether you can win. The infringer’s business intelligence tells you whether winning is worth anything.

How Patent Damages Actually Work

Under 35 U.S.C. § 284, a court that finds infringement must award “damages adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer.” The statute sounds like a floor. In practice, it is also a ceiling shaped by the defendant’s economics.

Damages in patent cases are calculated in two primary ways: lost profits — what the patent owner would have made but for the infringement — and reasonable royalty — a hypothetical license fee reconstructed from the Georgia-Pacific factors, applied as though the parties had negotiated in good faith at the time infringement began. Most licensing-out cases involving non-practicing entities default to reasonable royalty, since lost profits requires showing direct market competition.

The reasonable royalty calculation is anchored to what the infringer actually generated from the patented feature. Courts apportion damages to the specific feature at issue, not the product as a whole. If the accused product has a thousand features and the patent covers one of them, the royalty base reflects the economic contribution of that feature — not the product’s total revenue. This is the apportionment doctrine, reinforced by the Federal Circuit’s consistent decisions limiting royalty bases to the value of the patented contribution.

The practical consequence is direct: if the infringer is a small company with limited revenue from the accused product, the recoverable damages are proportionally small. A factually strong claim chart against a company generating $2 million in annual revenue from an infringing product does not produce the same damages exposure as the same claim chart against a company generating $200 million.

Patent litigation costs between $1.5 million and $5 million through trial, depending on jurisdiction and complexity, according to the AIPLA’s biennial Economic Survey. For cases where damages at risk are below $1 million, total litigation costs per side run $700,000 to $1.5 million. The math is unforgiving: if the damages ceiling is below the cost floor, the case is commercially negative before it reaches the courthouse steps.

If the damages ceiling is below the cost floor, the case is commercially negative before it reaches the courthouse steps.

What the Cases Show

The relationship between infringement strength and commercial outcome is not hypothetical. It is demonstrated repeatedly in the litigation record. Two cases are instructive precisely because they do not involve weak patents or close infringement questions — both involve infringement findings that were factually upheld. The problem was not the strength of the legal case. It was the mismatch between the legal outcome and the commercial reality.

Case Study 1 — Lucent Technologies v. Gateway (2003–2011)

Lucent Technologies sued Gateway, Dell, and Microsoft over the “Day patent” — a method for entering data into computer screen fields without a keyboard, covering features in Microsoft Outlook, Microsoft Money, and Windows Mobile.

A jury confirmed infringement and awarded Lucent $357.7 million in damages. The validity and infringement findings were upheld by the Federal Circuit. But the damages award was vacated. The court found the award lacked sufficient evidentiary support: the patented feature was one of hundreds of features in the accused software, and Lucent had not demonstrated that it drove consumer demand. The case was remanded for a new damages trial. After further proceedings, damages were reduced to $70 million, then cut again to $41 million.

The lesson is not that the patent was weak. The patent was valid and infringed. The lesson is that even against a defendant with Microsoft’s revenue, the damages recoverable from a single feature embedded in a complex product — absent a showing that the feature drove demand — were subject to radical compression over the life of the case.

From first filing to resolution, Lucent spent the better part of a decade in litigation. The distance between the jury’s $357.7 million and the eventual settlement around $41 million illustrates how the same infringement finding produces materially different commercial outcomes depending on how the defendant’s economics are constructed and contested.

Case Study 2 — SimpleAir v. Google (2011–2016)

SimpleAir, an inventor-owned technology licensing company, sued Google in 2011 alleging that Google’s Cloud Messaging services infringed its data transmission patent. A jury found infringement on all five asserted claims and confirmed validity. A separate damages jury awarded $85 million.

Google appealed. The Federal Circuit reversed the infringement finding entirely — not on validity, but on claim construction. The key term “data channel” was construed to require a separate communication path from standard internet traffic. Under that construction, Google’s system did not infringe as a matter of law. SimpleAir recovered nothing.

The case illustrates a different version of the same structural problem. The legal infringement finding at the trial level was real. The commercial exposure to Google was substantial. But the defendant’s resources enabled an appeal that turned on a single claim construction question — and the entire damages award was extinguished. SimpleAir had accumulated years of litigation costs against a defendant whose revenue made the fight commercially rational for Google to pursue at every stage.

The inverse of this case is the one that never gets filed: the same patent, the same infringement, and a defendant without Google’s resources. That case may produce a faster settlement — or a verdict that does not cover the cost of obtaining it.

Together, these cases illustrate the same structural truth from different angles. The infringement question and the damages question are related but not identical. A strong claim chart is the predicate to a legal win. It does not determine the commercial value of that win. The defendant’s revenue, the portion of that revenue attributable to the patented feature, and the defendant’s capacity to sustain and complicate litigation are the variables that actually govern the outcome.

Why This Plays Out Differently Across Industries

The relationship between infringement strength and commercial outcome varies systematically across industries. The underlying mechanism is consistent: damages are bounded by what the infringer earned from the patented feature. But what that means in practice depends on the structure of the industry, the role of the patent in the product, and how damages are calculated within that sector.

In pharmaceuticals and biotech, the patented claim frequently maps directly to the active compound or the core formulation. There is no meaningful apportionment question: the patent covers the product, not a feature of the product. This means that a reasonable royalty or lost profits calculation is applied against the full revenue of the infringing product. A generic manufacturer infringing a drug patent is infringing against the entire economic value of that drug — not against one line in a thousand-feature software package. This is why pharmaceutical patent litigation produces the largest damages awards and the most commercially viable licensing programs. The infringer’s revenue from the accused product is the royalty base.

In software and AI products, apportionment is the controlling problem. Modern software products contain hundreds or thousands of functional components, many of which could be individually patented by different parties. A patent on a specific feature — a notification mechanism, a data compression method, a UI input approach — covers a fraction of what makes the product commercially valuable. Courts have become increasingly strict in requiring patent owners to apportion their royalty base to the specific contribution of the patented feature. The consequence is that infringement of a real and valid patent by a high-revenue software product may produce recoverable damages far below what intuition would suggest. The Lucent case is a direct illustration of this: infringement was confirmed against one of the most profitable software companies in the world, and the eventual commercial outcome was a fraction of what the initial jury verdict suggested.

In manufacturing and hardware, the picture is more variable. Where the patent covers a core process or a structural component that defines the product’s function, damages can be substantial. Where the patent covers one element of a multi-component assembly, apportionment applies in the same way it does in software. The key variable is whether the patented claim goes to what the product is or to one thing the product does.

Across all three sectors, the commercial viability of a licensing-out strategy is ultimately determined by the same question: how much revenue is the infringer actually generating from the specific feature or compound covered by the claim? That question is not answered by the claim chart. It is answered by business intelligence on the accused infringer and its product economics.

The infringer’s revenue from the accused product is the royalty base. That number does not appear in the claim chart.

The Licensing-Out Strategy Problem

Patent owners pursuing licensing-out strategies typically begin with the same analysis: identify potential infringers, map claims against accused products, assess the strength of the infringement case, and prioritize targets based on claim coverage. This is a legally coherent process. It answers the legal question with the appropriate tools.

The commercial question requires a different data layer.

A licensing-out strategy is a revenue-generation program, not a legal enforcement program. The distinction matters. Revenue generation depends on what the target can pay, what they are likely to pay to avoid litigation, and whether the economics of pursuing a claim against them make sense before the first letter goes out. None of those variables are visible in the claim chart.

What they require is business intelligence on the accused infringer: the company’s size and financial position, the revenue attributable to the accused product, the product’s market position and growth trajectory, whether the company has the resources to sustain prolonged litigation, and whether the commercial relationship being pursued is realistically a licensing negotiation or a litigation campaign that will cost more than it recovers.

The difference between a licensing target and a litigation money-loser can be invisible at the claim chart level. Two companies with identical infringement profiles produce entirely different commercial outcomes if one generates $50 million from the accused product and the other generates $500,000. The claim chart is the same. The licensing strategy should not be.

This is the structural gap that most patent owners — and many IP teams — underestimate. The investment in claim construction, prior art search, and FTO analysis is substantial and appropriate. The parallel investment in understanding who the target is as a business — what they earn, what they are worth, and what their litigation posture is likely to be — often does not happen until the economics become uncomfortable.

Why Business Intelligence Is the Missing Layer in Licensing-Out Strategy

At PioneerIP, we built our patent-to-product comparison engine to close the gap between IP legal analysis and the business decisions that IP analysis is supposed to inform. The claim chart is the starting point, not the conclusion. What comes after — the assessment of whether pursuing a target is commercially rational — requires a different kind of data.

The BI report that PioneerIP generates alongside the infringement analysis is designed to answer exactly this question: what is the accused infringer worth as a licensing target? That means understanding the company’s revenue profile, the commercial footprint of the accused product, the financial position that would determine a realistic licensing floor, and the litigation risk profile that shapes the negotiating dynamic.

A claim chart with strong element-by-element mapping against a company with $200,000 in annual revenue from the accused product is not a licensing opportunity. It is a cost center. The same claim chart against a company generating $20 million from the same product is a different conversation entirely. The legal analysis does not change. The commercial decision does.

This is the reason reliance on claim chart quality alone is insufficient as the basis for a licensing-out strategy. The claim chart establishes the legal predicate. The business intelligence determines whether exercising that predicate makes economic sense. A licensing-out program that skips the second step will consistently produce one of two outcomes: targets that settle for amounts below the cost of pursuit, or targets with the resources to make the litigation expensive enough to neutralize the economics.

The question that should precede every licensing campaign is not only “can we prove infringement?” It is “what would winning actually be worth — against this specific defendant, with this specific revenue profile, in this specific market context?”

That question is not answered in the claim chart. It is answered in the business intelligence layer that most licensing-out strategies still treat as optional.